AI stock analysis · Drug Manufacturers - Specialty & Generic · Last analyzed Aug 18, 2026
Compass Score
3.0/5
Call
Hold
Price
$72.97
AI Target
$100.94 +38.3%
AI Analyst Summary
Zoetis trades at a strikingly low 12.0x trailing P/E for a dominant animal health platform, suggesting the market is pricing in a prolonged growth slowdown — which may create a mean-reversion opportunity if management can reignite revenue momentum. However, with earnings growing just 1.2% YoY, revenue declining -0.2%, and a PEG ratio of 6.61, the near-term fundamental backdrop does not yet support the bull case. The key risk is that growth stagnation persists longer than expected, keeping the stock range-bound despite its apparent valuation cheapness.
Catalysts
Reacceleration of companion animal product revenue driven by the parasiticide and dermatology portfolios (Simparica Trio, Apoquel, Cytopoint) in upcoming quarterly results
Pipeline progression in monoclonal antibody treatments for osteoarthritis pain in dogs and cats, which could unlock a significant new revenue stream in H2 2025
Potential margin expansion from ongoing cost optimization and operating leverage if revenue growth returns to mid-single digits, re-rating the PEG ratio toward fair value
Trailing P/E of 12.0x and forward P/E of 11.0x are materially below the healthcare sector median and represent compelling valuation for a high-quality animal health franchise. Significant discount to intrinsic value if growth normalizes.
PegPEG Ratio: 6.61 · 1.0/5
PEG of 6.61 is well above the 3.0 threshold for a score of 1, signaling that even the low P/E is not justified by near-term earnings growth. Current earnings momentum is too weak to support this multiple on a growth-adjusted basis.
Analyst RatingBuy consensus (2.2) · 4.0/5
Consensus of 2.2 maps to a score of 4, reflecting a constructive analyst community with 10 Buys and 9 Holds across 16 analysts. No Sell ratings suggest limited near-term downside concern among covering analysts.
Earnings growth of just 1.2% YoY alongside a slight revenue contraction of -0.2% signals a near-stall in the business. Growth is far below the 25% threshold for a high score and is not accelerating, warranting a below-average rating.
Only 4 quarters of data available, so this is scored conservatively. Beating in 3 of 4 recent quarters shows reasonable execution, but insufficient history to award a higher score with confidence.
Management demonstrates adequate near-term execution with a 3-of-4 beat rate, but the stalling top-line and tepid earnings growth raise questions about capital allocation effectiveness and near-term strategic momentum. Analyst confidence is constructive but not emphatic.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.